TP
REGN icon

TritonPoint Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

TritonPoint Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Buy
+619
New +$421K 0.03% 253

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TritonPoint Partners's REGN Position: Q2 2026 in Review

TritonPoint Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 619 shares worth $386K. The stake represents 0.03% of the portfolio and ranks #253 among its holdings.

1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • TritonPoint Partners held 619 shares of Regeneron Pharmaceuticals worth $386K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new TritonPoint Partners position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.03% of TritonPoint Partners's portfolio in Q2 2026, its #253 holding.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on TritonPoint Partners's 13F filing for Q2 2026, filed 13 Aug 2026.